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Human herpesvirus 8 (HHV-8)/Kaposi’s sarcoma-associated herpesvirus infection goes through lytic and
latent phases that are regulated by viral gene products, but very little is known about the involvement of host
proteins. The replication and transcription activator (RTA) is a viral protein sufficient to initiate lytic
replication by activating downstream genes, including the viral early gene open reading frame 57 (ORF 57),
which codes for a posttranscriptional activator. In this study, we demonstrate that cellular interferon regulatory factor 7 (IRF-7) negatively regulates this process by competing with RTA for binding to the RTA
response element in the ORF 57 promoter to down-regulate RTA-induced gene expression. We also show that
alpha interferon represses RTA-mediated transactivation and that repression involves IRF-7. Our study
indicates that upon HHV-8 infection, the host responds by suppression of lytic gene expression through binding
of IRF-7 to the lytic viral gene promoter. These findings suggest that HHV-8 has developed a novel mechanism
to induce but then subvert the innate antiviral response, specifically the interferon-signaling pathway, to
regulate RTA activity and ultimately the viral latent/lytic replicative cycle.
RTA contains an amino-terminal basic DNA-binding domain
and a carboxy-terminal acidic activation domain (28, 45). The
activation is mediated by interaction with different viral gene
promoters via a sequence-specific motif know as the RTA
response element (RRE) (9, 29, 42). It was recently suggested
that the subunits of an RTA oligomer may make multiple
contacts with a tandem repeat of the core sequences (25).
RTA activates the expression of a number of viral immediate-early and early genes, including its own and several others,
such as an early gene, ORF 57 (3, 7, 9, 29). ORF 57 is a
homologue of Epstein-Barr virus (EBV) MTA (the M transactivator, BMLF1) and encodes a posttranscriptional activator,
which acts as an mRNA export factor. The ORF 57 gene
product is thought to bind viral RNA to facilitate mRNA
transport from the nucleus to the cytoplasm (1, 19). The result
of this transport is modulation of viral gene expression, especially of the intronless late structural genes. For EBV and
herpesvirus saimiri, the ORF 57 homologue has been shown to
be essential for production of infectious virions (11, 49). Thus,
the regulation of ORF 57 expression by RTA plays a critical
role in viral infection and maintenance of the balance between
latency and lytic reactivation.
Viral infection induces the expression of interferons (IFNs)
and other cytokines. The effects of IFN on cells are mediated
by IFN-stimulated genes (ISGs), including a family of IFN
regulatory factors (IRFs). To date, 10 cellular IRFs have been
identified (30, 32, 44). The hallmark of cellular IRFs is an
N-terminal DNA binding domain, which contains a tryptophan-rich region and forms a helix-turn-helix motif that interacts with IFN-stimulation response elements (ISREs) in target
gene promoters (44). IRFs play a critical role in the activation
of other cellular genes, such as those encoding alpha interferon

Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), is a recently discovered
human gammaherpesvirus, which was first identified in AIDSassociated Kaposi’s sarcoma (KS) tissues (5). HHV-8 is the
etiological agent of KS and is associated with two other lymphoproliferative disorders, primary effusion lymphoma (PEL)
and multicentric Castleman’s disease (4, 8). Like other herpesviruses, HHV-8 exhibits two distinct phases of infection: lytic
and latent. During latency, viral gene expression is limited to a
few tightly controlled genes. These genes are thought to maintain the viral episome, promote immune evasion, and provide
a growth advantage to the infected cells (16, 40). Latency
enables the virus to establish persistent infection and plays a
major role in tumorigenesis (34). The expression of the full set
of viral genes occurs only during lytic replication, when virus
progeny are produced and the host cell is destroyed (39). Lytic
reactivation enables the spread of viruses from the lymphoid
compartment to endothelial cells, which plays a role in the
development of KS (12, 17).
HHV-8-infected PEL cells harbor the virus in a latent state
from which it can be activated to enter lytic replication by
treatment with sodium butyrate or 12-O-tetradecoylphorbol
13-acetate (TPA). Control of latent-lytic switching is maintained by the HHV-8 replication and transcription activator
(RTA), produced from HHV-8 open reading frame 50 (ORF
50). Expression of HHV-8 RTA is necessary and sufficient to
disrupt viral latency and induce lytic replication (10, 27, 43).
* Corresponding author. Mailing address: Nebraska Center for Virology and School of Biological Sciences, University of NebraskaLincoln, E249 Beadle Center, 1901 Vine St., Lincoln, NE 68588-0666.
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(IFN-␣) and IFN-␤, IFN-stimulated genes, and genes encoding several chemokines (30, 53). Addition of IFN-␣ inhibits
HHV-8 reactivation in PEL cells and reduces the HHV-8 load
in cultured peripheral blood mononuclear cells (33); this effect
is likely to be mediated by a number of cellular factors including IRFs. One IRF implicated in HHV-8 infection is IRF-7,
since it is strongly up-regulated during the early lytic cycle of
HHV-8 in human endothelial cells, fibroblast cells, and B cells
including the BCBL-1 PEL cell line (36, 38). The IRF-7 gene
is induced by IFN through the IFN-stimulated gene factor 3,
after which IRF-7 undergoes nuclear translocation, where it
activates both IFN-␣ and IFN-␤ expression (32, 44). Since
IRF-7 is induced early in HHV-8 infection, its role in augmenting viral replication and its effects on immediately-early viral
gene expression warrant investigation.
Our previous studies have shown that HHV-8 RTA activates
viral ORF 57 gene expression (45). This activation is mediated
by the binding of RTA to a 40-bp region within the ORF 57
promoter. The activation of ORF 57 by RTA then contributes
to lytic viral replication. In this study, we demonstrate that
RTA-mediated transactivation of ORF 57 gene expression can
be negatively regulated by IRF-7. This level of control occurs
via competitive binding of IRF-7 to the RRE in the ORF 57
promoter. The present study suggests that HHV-8 has adopted
a strategy for utilizing a component of the host innate immune
response to facilitate suppression of early lytic gene expression
and to promote latency and persistent infection.
MATERIALS AND METHODS
Plasmids. Expression plasmids pcDNA-ORF50, which encodes the full-length
HHV-8 RTA, and pCMV-Tag50, which encodes a Flag-tagged RTA, were described previously (45). The p57Pluc1 reporter, containing the 453-bp HHV-8
ORF 57 promoter region (nucleotides (nt) 81556 to 82008), was also described
previously (45). IRF-7 expression plasmids pcDNA-IRF-7A, pcDNA-IRF-7C,
and pcDNA-IRF-7DN, expressing different spliced isoforms of IRF-7, were
described elsewhere (50, 51). pCMV-Tag7A and pET28a-IRF7A, which encode
the Flag tag- and His tag-fused IRF-7, were created by amplifying the full-length
IRF-7 coding region from pcDNA-IRF-7A using 5⬘ primer (5⬘ AGGAT CCAT
GGCCTTGGCTCCTGAG 3⬘) and 3⬘ primer (5⬘ TGGGCTGCTCGAGCTTT
CTGGAGTTC 3⬘) and inserting the PCR products into pCMV-Tag2B (Stratagene, La Jolla, Calif.) or pET-28a (Novagen, Madison, Wis.) at the BamHI and
XhoI sites. The RTA coding sequence of pCMV-Tag50 was inserted into pET28b (Novagen) to generate pET28b-RTA for expression of His-tagged RTA in
Escherichia coli. p57Pluc1m, with mutation in the potential IRF-7 binding site,
was generated by using a site-directed mutagenesis kit (Stratagene). An IRF-7
RNA interference construct, pGE1-IRF-7i, was obtained by inserting the annealed product of 5⬘ GATCCCGCTGTGACACCCCCATCTTCGACTTCAGA
GGAA GCTTGCTCTGAAGTCGAAGATGGGGGTGTCACAGTTTTTT 3⬘
and its complementary strand, 5⬘ CTAGAAAAAACTGTGACACCCCCATCT
TCGACTTCAGAGCAAGCTTCCTCTGAAGTCGAAGATGGGGGTGTCA
CAGCGG 3⬘, into the pGE-1 vector (Stratagene) at the BamHI and XbaI sites.
The ␤-galactosidase expression plasmid pCMV-␤ was purchased from Clontech
(BD Biosciences, Palo Alto, Calif.). All PCR generated plasmids, mutations, and
fusion protein expression plasmids were verified by sequence analysis.
Cell culture, transfection, and luciferase assays. The human embryonic kidney
fibroblast cell line 293T was cultured in Dulbecco’s modified Eagle medium
(Mediatech, Herndon, Va.) supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin-streptomycin at 37°C in 5% CO2. Transfection was carried out
with LipofectAMINE reagent (Invitrogen, Carlsbad, Calif.) as described previously (6). The total amount of transfected DNA in each well was kept constant
by the addition of control vector plasmid. Transfected cells were harvested 48 h
posttransfection. The luciferase activity was measured with a luciferase assay
system (Promega, Madison, Wis.). Transfection efficiency was normalized by
using a pCMV-␤-gal expression plasmid as an internal control. The mean luciferase values were derived from at least three independent transfection assays.
BCBL-1 is an HHV-8-positive PEL cell line. TRE⫻BCBL-1 is a BCBL-1 cell
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line carrying a gene-inducible system, and TRE⫻BCBL-1 RTA is a
TRE⫻BCBL-1 cell line carrying a tetracycline-inducible RTA gene (35). BJAB
and DG75 are HHV-8- and EBV-negative Burkitt’s lymphoma cell lines (2, 31).
These cell lines were maintained in RPMI 1640 (Mediatech) plus 10% FBS and
1% penicillin-streptomycin at 37°C with 5% CO2. B cells were transfected by
electroporation at 250 V and 960 F in 0.4 ml of RMPI 1640 medium without
FBS as described previously (52). The total amount of electroporated DNA in
each cuvette was kept constant by the addition of control vector plasmid. Cells
were collected at 72 h postelectroporation. Luciferase activities were measured
with a luciferase assay system (Promega). Electroporation efficiency was normalized by using a pCMV-␤-gal expression plasmid. Each result was obtained from
an average of at least three independent experiments.
Expression and purification of recombinant proteins. E. coli BL21(DE3) cells
harboring the pET28b-RTA or pET28a-IRF7A plasmid were cultured overnight
at 37°C in 5 ml of Luria-Bertani broth containing 50  of kanamycin/ml. Each
500 ml of Luria-Bertani broth containing 50-g/ml kanamycin was inoculated
with 5 ml of an overnight culture and grown for 3 to 4 h at 37°C until the culture
reached an A600 of 0.8. Protein expression was induced for 4 h with 0.1 to 0.5 mM
isopropylthio-␤-D-galactoside at 28°C. The cells were then harvested by centrifugation, resuspended in 5 ml of lysis buffer (50 mM NaH2PO4, 0.3 M NaCl, 10
mM imidazole [pH 8.0]) with 0.5 mM phenylmethylsulfonyl fluoride. After sonication and centrifugation, the His-tagged RTA or His-tagged IRF-7 proteins in
the supernatant were purified with Ni2⫹-nitrilotriacetic acid agarose (QIAGEN,
Valencia, Calif.) under native conditions. Proteins in each fraction were analyzed
by Western blotting with an anti-His6 monoclonal antibody–horseradish peroxidase conjugate (BD Biosciences). Fractions containing RTA or IRF-7 were
dialyzed against phosphate-buffered saline (pH 7.4), divided into aliquots, and
stored at ⫺70°C.
Mammalian-derived recombinant IRF-7 protein was purified from transfected
293T cell extract. 293T cells in 100-mm-diameter dishes were transfected with 5
g of pCMV-Tag7A. Cells were collected, washed twice with 1⫻ TBS (50 mM
Tris-HCl, 150 mM NaCl [pH 7.4]), and then lysed in 2 ml of 1⫻ lysis buffer (50
mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 [pH 7.4]). Flagtagged IRF-7 was bound to anti-Flag M2 affinity gel (Sigma, St. Louis, Mo.),
washed with 1⫻ TBS, eluted with 20 mM glycine-HCl at pH 3.0, and then
immediately neutralized with 1 M Tris-HCl (pH 8.0). Eluted fractions were
analyzed by Western blotting with anti-Flag M2 antibody (Stratagene). FlagIRF-7 proteins were divided into aliquots and stored at ⫺70°C.
Antibodies and Western blot analysis. Anti-Flag M2 antibody was purchased
from Stratagene; anti-His6 monoclonal antibody–horseradish peroxidase conjugate was purchased from BD Biosciences; anti-␤-tubulin antibody was purchased
from Sigma. Anti-RTA, anti-ORF 57, and anti-IRF-7 antibodies were described
previously (37, 46, 50). For Western blot analysis, the Hybond-P membrane and
ECL detection reagents (Amersham, Piscataway, N.J.) were used.
EMSA. The probes were obtained by annealing complementary oligonucleotides and then labeling with [␣-32P]dATP (Amersham), using DNA polymerase
I Klenow fragment (Fermentas, Hanover, Md.). The 57I, 57R, and 57IM probes
are as described in Fig. 1. The AP1 probe was purchased from Promega. The
consensus ISRE probe from ISG-15 and the PAN probe were synthesized according to previous reports (18, 41). The Tap-2 ISRE and Tap2m ISRE probes
were described earlier (52). The electrophoretic mobility shift assay (EMSA) was
performed essentially as described previously (52). Purified RTA protein or
IRF-7 protein was incubated with 20,000 to 50,000 cpm of labeled probe in a
volume of 12.5 l containing 20 mM HEPES-KOH, 1 mM MgCl2, 0.1 mM
EGTA, 2 g of poly(dIdC), and 4% Ficoll 400 (pH 7.9) for 20 min at room
temperature. For competition assays, a 50-fold excess of cold probe was added to
the binding mixture. For super-shift assay, 0.1 l of rabbit anti-IRF-7 antibody
was added 10 min before the addition of the probe. The binding mixtures were
loaded onto a 4.5% polyacrylamide gel in 0.25⫻ TBE buffer (22.5 mM Trisborate, 0.5 mM EDTA), and the gel was run at 4°C and then dried onto a piece
of Whatman 3MM paper (Whatman, Clifton, N.J.) followed by autoradiography.

RESULTS
The HHV-8 ORF 57 promoter has a functional IRF-7 binding site. The expression of ORF 57 is regulated by RTA and is
mediated by the binding of RTA to RREs located within the
ORF 57 promoter. Analysis of the RREORF57 sequence revealed a potential IRF-7 binding site, 5⬘-ATTTTTCGTTTG3⬘, at nt 81930 to 81941 in the HHV-8 BC-1 genome (Fig. 1).
The complementary sequence is identical to the consensus
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FIG. 1. RTA response element and putative IRF-7 binding site in
the HHV-8 ORF 57 promoter. The locations of various putative promoter-regulatory elements and the EBV RRE-like sequences are indicated on the promoter segment. The sequence of 40-bp RRE region
is boxed, the identical nucleotides shared between ORF 57 RRE and
ORF K8 RRE are italicized, and the putative IRF-7 binding site is
shadowed. Two IRF-7 binding consensus sequences are also shown
(complementary sequences of cloned IRF-7 binding sites by Lin et al.
[26]). The p57Pluc1m mutant plasmid with mutations in the potential
IRF-7 binding site was identical to the p57Pluc1 reporter construct
except for the highlighted region, with changes shown in lowercase.
The bold lines indicate the region of probes corresponding to the
RREORF57 sequence.

IRF-7 binding sequence, 5⬘-GAA(A/T)N(C/T)GAAAN (T/C)
-3⬘ (26), except where the first G residue in the consensus is
replaced by a C residue and the last T/C residue is replaced by
an A residue (Fig. 1). Similar substitutions have been described
previously (26). The presence of a potential IRF-7 binding
sequence in the ORF 57 promoter suggested that IRF-7 might
bind and regulate ORF 57 expression.
To determine whether IRF-7 binds to this consensus sequence, EMSAs were performed by using a labeled doublestranded oligonucleotide, 57I, from nt 81928 to 81946 in the
ORF 57 promoter sequence (Fig. 1). Binding was detected by
using bacterially expressed, His-tagged IRF-7 protein (Fig. 2A,
lane 2). Only very weak binding was detected with 57IM, a
probe containing a mutant IRF-7 binding site, and no binding
was detected with 57R, a probe that contains the 5⬘ region of
the RREORF57 but not the putative IRF binding site (Fig. 2A,
lanes 4 and 6). The addition of the specific competitor, 57I,
significantly decreased binding of IRF-7 to the labeled probe
(Fig. 2B, lane 3), the mutated competitor 57IM only had minor
inhibitory effect, and 57R did not compete (Fig. 2B, lanes 4 and
5). The addition of either an IRF-7 consensus binding target,
ISRE oligonucleotide (Fig. 2B, lane 6), or another known
IRF-7 binding site, Tap2 oligonucleotide (Fig. 2B, lane 7),
inhibited IRF-7 binding to the 57I probe, with Tap2 inhibiting
more effectively. A mutant Tap2 probe, Tap2m, did not inhibit
complex formation (Fig. 2B, lane 8). An unrelated oligonucleotide probe, AP1, did not inhibit binding (Fig. 2B, lane 9).

J. VIROL.

Addition of an anti-IRF-7 antibody supershifted the IRF-7DNA complex (Fig. 2B, lane 10), but an antibody to another
HHV-8 gene product, anti-K15, did not (Fig. 2B, lane 11).
Given the specific binding of IRF-7 to the ORF 57 promoter, it seemed plausible that IRF-7 might regulate ORF 57
gene expression. To identify the effect of IRF-7 on ORF 57
expression, we measured the activity of an ORF 57 promoterreporter construct in the presence of exogenous IRF-7 in 293T
cells which expressed very little endogenous IRF-7. The expression of Flag-tagged IRF-7 was monitored by Western blotting, using anti-Flag antibody. Increasing amounts of IRF-7
expression plasmid (0 to 1 g) resulted in dose-dependent
increases of ORF 57 promoter activity, but only 10-fold activation was observed with the highest concentration of IRF-7
added (Fig. 2C). To confirm the specificity of the interaction
between IRF-7 and the ORF 57 promoter, the p57Pluc1m
mutant plasmid, identical to the p57Pluc1 reporter construct
except for mutations in the potential IRF-7 binding site, was
generated (Fig. 1). Mutation of the IRF-7 binding site within
the ORF 57 promoter abolished its responsiveness to IRF-7
(Fig. 2C). Based on our observation that IRF-7 binds to the
consensus IRF-7 binding motif in the ORF 57 promoter and
results in some enhancement of ORF 57 promoter-mediated
gene expression, we hypothesized that the ORF 57 promoter
has a functional IRF-7 binding site, the binding of which may
regulate ORF 57 expression.
IRF-7 suppresses RTA activation of ORF 57 gene expression. Since the IRF-7 binding site in the ORF 57 promoter
overlaps with the RRE and the binding of IRF-7 enhances
ORF 57 expression, it was important to investigate the interplay between IRF-7 and RTA on the RTA-responsive ORF 57
promoter. To examine this potential interaction, the p57Pluc1
reporter plasmid was transfected into 293T cells with a fixed
amount of pCMV-Tag50, an RTA expression plasmid, and
with increasing amounts of pCMV-Tag7A. The expression levels of Flag-tagged RTA and IRF-7 proteins were detected by
Western blotting with anti-Flag antibody. As expected, the
ORF 57 promoter was strongly activated by HHV-8 RTA;
however, when increasing amounts of the IRF-7 expression
plasmid pCMV-Tag7A were added, the RTA-mediated ORF
57 activation was repressed in a dose-dependent manner (Fig.
3A). RTA activation was reduced by 77% when 2 g of IRF-7
expression plasmid was added. The reduction of RTA activity,
however, was not due to an IRF-7-mediated diminution in
RTA expression, since similar levels of RTA were expressed
(Fig. 3A).
To confirm that the repression of RTA by IRF-7 is specific,
the p57Pluc1 reporter plasmid was transfected into 293T cells
with a fixed amount of pCMV-Tag7A and with increasing
amounts of pCMV-Tag50 (Fig. 3B). As expected, the activation of ORF 57 expression by RTA was inhibited by IRF-7, but
the inhibition was less effective with increasing amounts of
RTA. Activation was repressed by 40% by IRF-7 when 25 ng
of RTA expression plasmid was added but only by 27% when
0.5 g of RTA was added.
IRF-7 repression of RTA transactivation was also observed
in B cells. In BJAB and DG75, two EBV/HHV-8-negative cell
lines, IRF-7 reduced RTA activation by 84 and 67%, respectively (Fig. 3C). To determine whether the suppression of RTA
activation of the ORF 57 promoter was specifically due to

FIG. 2. IRF-7 binds to the putative IRF-7 binding site of the ORF 57 promoter. (A) EMSA of the 57I, 57IM, and 57R probes with IRF-7
protein. Partially purified His-tagged IRF-7 was incubated with labeled probes: 57I (lanes 1 and 2), 57IM (lanes 3 and 4), or 57R (lanes 5 and 6).
The open arrow indicates specific binding of IRF-7. (B) Competitive binding and super-shift assays of the IRF-7–57I complex. A 50-fold excess
of specific competitors (57I in lane 3, ISRE in lane 6, and Tap2 in lane 7) and nonspecific competitors (57IM in lane 4, 57R in lane 5, Tap2m in
lane 8, and AP1 in lane 9) were used. Rabbit anti-IRF-7 (lane 10) and anti-K15 (lane 11) antibodies were also used. The open arrow indicates the
specific binding of IRF-7. The shaded arrow indicates the super-shift of IRF-7. (C) IRF-7 binding site in the ORF 57 promoter is critical for IRF-7
response. Twenty nanograms of p57Pluc1 or p57Pluc1m was cotransfected into 293T cells with various amounts of IRF-7 expression plasmid
pCMV-Tag7A, and luciferase activities were tested. In parallel, protein expression was detected by Western blotting using anti-Flag and
anti-␤-tubulin monoclonal antibodies. The numbers above each bar represent n-fold activation and are normalized to 1 in the absence of IRF-7.
Results are averages from at least three independent experiments, and the standard deviations are shown.
2423
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FIG. 3. IRF-7 represses RTA-mediated transactivation. (A) Transactivation of p57Pluc1 by RTA is repressed by IRF-7 in 293T cells. The cells
were cotransfected with pCMV-Tag50 and pCMV-Tag7A. Luciferase activity and Western blot analysis were carried out. (B) Repression of
RTA-mediated transactivation by IRF-7 at different RTA-to-IRF-7 plasmid DNA ratios. DNA transfection was carried out as described for panel
A, with a fixed amount of pCMV-Tag7A and increasing amounts of pCMV-Tag50. (C) Repression of RTA transactivation by IRF-7 in B cells.
BJAB or DG75 cells were electroporated with pCMV-Tag50 and pCMV-Tag7A. The luciferase activities were measured. (D) Repression of
RTA-mediated transactivation can be prevented by addition of IRF-7i. 293T cells were cotransfected with pCMV-Tag50, pCMV-Tag7A, and
various amounts of IRF-7i construct. Luciferase activities were measured, and Western blot analysis was carried out.

IRF-7, an IRF-7 RNA interference plasmid, pGE1-IRF-7i,
was used to inhibit IRF-7 expression. Fewer RTA and IRF-7
expression plasmids were used in the study, since RNA interference assays required a high ratio of IRF-7i construct to
IRF-7 plasmid to give maximum efficiencies in silencing. For
RTA expression, twofold less plasmid used in the experiment
resulted in fourfold less RTA protein expressed and fivefold
less transactivation activity (compare Fig. 3A and D, lanes 2),
and the transactivation was inhibited by about 50% upon cotransfection with 100 ng of IRF-7 expression plasmid (Fig. 3D,
lane 3). With increasing amounts of pGE1-IRF-7i added,
IRF-7 expression levels were reduced, and the inhibitory ef-

fects of IRF-7 on RTA transactivation were proportionally
reversed (Fig. 3D).
Interaction between the IRF-7 binding site in RREORF57 and
the DNA binding domain of IRF-7 mediates the repression of
RTA transactivation. Since it appeared that IRF-7 repression
was mediated through binding to the promoter region, we
sought to investigate the role of this IRF-7 binding site in
IRF-7 interference with RTA activation of a mutant ORF 57
promoter construct, p57Pluc1m (Fig. 1). RTA transactivated
the mutant p57Pluc1m much less than wild-type p57P1-luc.
The addition of IRF-7 failed to inhibit the activation of
p57Pluc1m by RTA (Fig. 4A), suggesting that IRF-7 inhibited
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FIG. 4. The IRF-7 binding site in the RRE of the ORF 57 promoter and the binding domain of IRF-7 are required for repression of
RTA-mediated transactivation. (A) The IRF-7 binding site in the ORF
57 promoter is critical for repression of RTA transactivation by IRF-7.
293T cells were cotransfected with the mutant ORF 57 promoter
construct p57Pluc1m, pCMV-Tag50, and various amounts of pCMVTag7A. Luciferase activities analysis was carried out. (B) IRF-7C represses RTA transactivation of the ORF 57 promoter. Transfections
were performed with IRF-7C and IRF-7DN expression plasmids. The
DBD of IRF-7C is indicated.

RTA activation of the ORF 57 promoter by binding to the
IRF-7 target site in the promoter region or by occupying or
occluding the RRE.
To identify the IRF-7 domains that are involved, two IRF-7
mutants were tested (Fig. 4B). IRF-7C retains the N-terminal
151-amino-acid DNA binding domain (DBD), and IRF-7DN
has lost the DBD but retains the activation domain. These two
IRF-7 variants were tested for their effects on ORF 57 promoter expression in the presence and absence of RTA. As
shown in Fig. 4B, IRF-7C was found to repress RTA-mediated
ORF 57 gene expression to the same level as full-length IRF-7,
whereas IRF-7DN failed to repress. Both IRF-7C and IRF7DN had no obvious effect on ORF 57 promoter activity when
transfected alone in the absence of RTA (Fig. 4B). These
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results suggest that IRF-7 represses RTA transactivation of the
ORF 57 promoter through the N-terminal DBD, whereas the
activation and regulation domains are not required.
IRF-7 can compete for RTA binding to the ORF 57 promoter. The expression of ORF 57 can be stimulated by RTA,
and the target site for RTA transactivation has been mapped
to a 40-bp sequence encompassing nt 81904 to 81943 in the
ORF 57 promoter (9, 29, 46, 47). The core element required
for RTA responsiveness consists of a conserved 12-bp palindromic sequence (Fig. 1). It was reported that RTA directly
binds to sequences within the palindrome, and both the palindrome and flanking sequences contribute to DNA binding and
transactivation by RTA (29).
We show here that IRF-7 binds to the 40-bp region in the
ORF 57 promoter and suppresses RTA-mediated activation;
therefore, it is possible that IRF-7 competes with RTA for
binding to this region and that such competition inhibits RTA
activation. To determine the role of the palindrome and flanking sequences in mediating DNA binding by RTA and by
IRF-7, two subfragments of the ORF 57 40-bp region, 57R and
57I (Fig. 1), were tested for binding to RTA and to IRF-7.
Both the 57R and 57I probes were found to bind RTA, as
indicated by the arrows in Fig. 5A and B. Interestingly, RTA
protein appears to bind to 57I better than the 57R probe when
the same amounts of probe and protein were added.
To confirm the binding of RTA to 57R and 57I, a competition assay was carried out with a 50-fold excess of an unlabeled
57I, 57R, PAN, or mutant (57IM) probe. The PAN probe was
tested because it also contains an RRE known to bind RTA.
The binding of RTA to both 57R and 57I probes was competed
by its homologous unlabeled probe and by the PAN probe
(Fig. 5A and B). Addition of the mutant 57IM probe (Fig. 5A,
lane 4) had little effect on RTA binding to 57R but could
reduce RTA binding to 57I by about 50% (Fig. 5B, lane 6),
suggesting that the mutations in the 57I probe did not abolish
RTA binding even though the binding of IRF-7 was affected
(Fig. 2B, lane 4). Indeed, RTA was found to bind to the 57IM
in EMSA (Fig. 5C, lane 2) where the addition of unlabeled
57IM and 57I competed for RTA binding. However, 57I appears to be more effective than 57IM (Fig. 5C, lanes 3 and 4),
confirming that RTA binds to 57I with higher affinity than
57IM.
Since IRF-7 and RTA bound the same 19-nt sequence in the
ORF 57 promoter (Fig. 2A and 5B), IRF-7 might compete
with RTA for binding to this site and thereby repress RTAmediated transactivation of the ORF 57 promoter. In order to
test this possibility, EMSA was carried out in the presence of
both RTA and IRF-7. Mammalian Flag-IRF-7 was used in
these experiments due to the similarity in size between E.
coli-expressed IRF-7 and RTA. As expected, in the absence of
IRF-7, RTA binds to the 19-nt 57I probe (Fig. 5D, lane 2; Fig.
5E, lane 6), but RTA binding was decreased as increasing
amounts of IRF-7 were added (Fig. 5D, lanes 3 to 5). In
parallel, IRF-7 binding decreased as increasing amounts of
RTA were added (Fig. 5E, lanes 3 to 5). No novel complex was
observed in the presence of both RTA and IRF-7, suggesting
that no stable protein-protein interaction between RTA and
IRF-7 forms in this assay system. This failure of IRF-7 and
RTA to directly interact was supported by coimmunoprecipitation and pull-down analysis (data not shown). Our results
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also indicate that the 19-nt 57I probe can accommodate either
IRF-7 or RTA but not both simultaneously. Therefore, IRF-7
can compete with RTA for binding to the IRF-7 binding site in
the ORF 57 promoter and vice versa.
Induction of IRF-7 by IFN-␣ is involved in the repression of
RTA-mediated transactivation of ORF 57 in HHV-8 infected
Cells. Previous reports have shown that IFN-␣ can inhibit the
expression of several viral genes and the accumulation of
HHV-8 DNA in BCBL-1 cells subsequent to TPA induction
(33). It is likely that this inhibition is mediated through IFN
response genes, such as IRFs. To determine whether IRF-7 is
involved in the suppression of lytic viral genes, such as ORF 57,
TRE⫻BCBL-1 RTA cells were cultured in the presence or
absence of IFN-␣ and then induced with tetracycline (Fig. 6A).
In this cell line, the RTA gene is integrated into the BCBL-1
genome, and RTA expression is tightly controlled by tetracycline (35). The tetracycline-induced His-tagged RTA protein
can be detected by anti-His6 antibody, and the expression of
viral RTA and ORF 57 can be detected specifically with antiRTA and anti-ORF 57 antibodies. IFN-␣ treatment induced
the expression of IRF-7 but did not alter the accumulation of
RTA. Concomitant with the increase in IRF-7, ORF 57 expression was reduced by more than 50% (Fig. 6A, lanes 2 and
3). In control TRE⫻BCBL-1 cells without integrated RTA,
IFN-␣ also induced the expression of IRF-7 as expected, but
the RTA expression was not stimulated by tetracycline, and
only very little ORF 57 expression was detected (Fig. 6A, lanes
5 to 8).
To confirm that IRF-7, but not other IRFs induced by
IFN-␣, is directly involved in repression of RTA-mediated
activation of the ORF 57 promoter, an RNA interference
construct, pGE1-IRF-7i, was used to specifically suppress
IRF-7 expression subsequent to IFN-␣ stimulation. BJAB or
DG75 cells were transfected with p57Pluc1 reporter plasmid,
pCMV-Tag50, and various amounts of IRF-7i construct and
then treated with IFN-␣. In the absence of IRF-7i, IRF-7 was
induced by IFN-␣, and the RTA-mediated activation of ORF
57 promoter activity was repressed by 83% in BJAB cells and
by 63% in DG75 cell (Fig. 6B). However, when pGE1-IRF-7i
was transfected, the IFN-␣-induced IRF-7 expression was reduced to an undetectable level. In parallel, the inhibitory effect
of IRF-7 on RTA transactivation was reversed in a dose-dependent manner (Fig. 6B). These results suggest that IRF-7,
but not other IRFs or other cellular genes, is responsible for
the repression of RTA-mediated transactivation subsequent to
IFN-␣ treatment.
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FIG. 6. IRF-7 is involved in repression of HHV-8 RTA-mediated
transactivation upon treatment by IFN-␣. (A) TRE⫻BCBL-1 RTA
cells were cultured for 24 h in the presence or absence of IFN-␣2b and
subsequently induced with 1 g of tetracycline/ml. At 8 h after induction, the cells were harvested and total protein (10 g) was analyzed by
Western blotting with the anti-His6, anti-RTA, anti-IRF-7, anti-ORF
57, and anti-␤-tubulin antibodies. The TRE⫻BCBL1 cells were
treated with tetracycline and used as negative controls. (B) BJAB or
DG75 cells were electroporated with pCMV-Tag50 and various
amounts of IRF-7i and subsequently cultured in the presence or absence of 100 U of IFN-␣2b/ml. Luciferase activity was measured. The
expression levels of IRF-7 and ␤-tubulin in cell lysate (10 g of total
protein) were analyzed by Western blotting using anti-IRF-7 and anti␤-tubulin antibodies.

FIG. 5. Competitive binding to the ORF 57 RRE by RTA and IRF-7. (A) RTA binds to the consensus region of the ORF 57 RRE. Partially
purified His-tagged RTA was incubated with labeled 57R probe. A 50-fold excess of specific competitors (57R in lane 3, 57I in lane 5, PAN in lane
6) and a mutated competitor (57IM in lane 4) were used. The arrow indicates the specific binding of RTA to the 57R probes. (B) RTA binds to
the IRF-7 binding site of the ORF 57 promoter. His-tagged RTA was incubated with labeled 57I probe. The arrow indicates the specific binding
of RTA to the 57I probe. A 50-fold excess of specific competitors (57I in lane 3, 57R in lane 4, PAN in lane 5) and a mutated competitor (57IM
in lane 6) were used. (C) EMSA of the 57IM probe with RTA. His-tagged RTA protein was incubated with labeled 57IM probe. The arrow
indicates the specific binding of RTA to the 57IM probe. A 50-fold excess of specific competitors (57IM in lane 3 and 57I in lane 4) was used.
(D) Competition of RTA binding to the 57I probe by IRF-7. His-tagged RTA (0.1 g) (lanes 2 to 5) was incubated with labeled 57I probe and
increasing amounts of Flag-IRF-7 (50 ng in lane 3, 0.15 g in lane 4, or 0.45 g in lanes 5 and 6). The open and shaded arrows indicate the binding
of RTA and IRF-7 to the 57I probe, respectively. (E) Competition of IRF-7 binding by RTA. Flag-IRF-7A protein (0.5 g) (lanes 2 to 5) was
incubated with labeled 57I probe and increasing amounts of His-tagged RTA (20 ng in lane 3, 60 ng in lane 4, or 0.2 g in lanes 5 and 6). Open
and shaded arrows indicate the specific binding of RTA and IRF-7 to 57I probe, respectively.
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DISCUSSION
Two key steps in the life cycle of all herpesviruses, including
HHV-8, are the establishment of latency and the ability to
reactivate from latency to lytic replication (34). For HHV-8,
ORF 50/RTA has been found to be sufficient to initiate lytic
gene expression in latently infected PEL cells (10, 27, 28, 43).
One of the genes affected by RTA is ORF 57, which is an
important viral lytic gene. ORF 57 is conserved, and its homologues can be found throughout the herpesvirus family members. These homologues include BMLF1 of EBV, IE63 of
herpes simplex virus type 1 (HSV-1), UL69 of human cytomegalovirus, ORF 57 of herpesvirus saimiri, and gene 4 of
varicella-zoster virus. For HSV-1, the ORF 57 homologue was
found to bind RNA in vivo, enhance RNA 3⬘ processing, inhibit pre-mRNA splicing, and perhaps facilitate the nuclear
export of HSV-1 transcripts. HHV-8 ORF 57 has trans-regulatory functions that appear to be mediated at the posttranscriptional level and are essential for production of infectious
virus (1). Thus, down-regulation of RTA-mediated ORF 57
expression is likely to have an effect on HHV-8 lytic replication. Even though we have found an IRF-7 binding site in the
HHV-8 ORF 57 promoter, it is not clear whether similar IRF-7
binding sites can be located within other ORF 57 homologous
genes. It is also not clear whether there are IRF-7 binding sites
located in other HHV-8 genes. A preliminary analysis of the
HHV-8 genome revealed a potential IRF-7 binding site located in the promoter of the K14 gene. Whether this is a
functional IRF-7 binding site and whether the binding of
IRF-7 modulates K14 gene expression need to be determined.
RTA not only is essential for viral reactivation but also plays
an important role in the pathogenesis of HHV-8 infection (8,
48). A number of previous studies have focused on elucidating
the mechanism whereby RTA induces lytic gene expression
(25, 29, 42, 48). The direct binding of RTA to specific promoter
RRE sequences was shown to contribute to the activation of
various early and late viral genes during lytic replication, and
the expression of these genes is modulated by the DNA binding affinity of RTA for the various target sites (42). A number
of cellular and viral coactivators have been described as playing
a role in RTA-mediated transcription activity, where most
were found to enhance lytic gene expression in the presence of
RTA (13, 14, 23, 24, 46, 47). These RTA-interacting factors
may also play a role in modulating the binding affinity of RTA
to its target sites.
In spite of what is known about the induction of lytic gene
expression by RTA, very little is known as to how RTA activities can be down-modulated in order for the virus to establish
or maintain latency. Whether down-regulation is mediated by
the repression of RTA expression or by the repression of RTA
transactivation function needs to be clarified. It was previously
reported that RTA-mediated gene expression can be downregulated by its interaction with histone deacetylase and latent
nuclear antigen and by the inhibitory effects of phosphorylation by kinases such as PARP-1 and hKFC (13, 15, 22). In this
study, we have further explored the mechanism whereby RTAmediated gene expression is modulated and found that IRF-7
can act as a competitor of RTA in regulation of ORF 57 gene
expression. The up-regulation of ORF 57 promoter-mediated
gene expression by RTA was suppressed in the presence of
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IRF-7 (Fig. 3) even though IRF-7 by itself is a weak transactivator of ORF 57 (Fig. 2). This inhibition is likely due to
competitive binding between IRF-7 and RTA, resulting in the
suppression of RTA recruitment onto the viral lytic ORF57
gene promoter region by IRF-7, followed by the inhibition of
RTA-mediated transcriptional activation and viral lytic replication.
The RRE in the HHV-8 ORF 57 promoter contains two RTA
binding sites, and IRF-7 acts as an RTA competitor for one of
the sites. The RRE of ORF 57 was previously characterized
and was found to be a target for either direct RTA binding or
indirect binding mediated by cellular factors, such as RBPj
(23, 24, 28, 42). The RRE has been mapped to a 40-bp region
which contains a consensus sequence found in the promoters
of other RTA-responsive genes, such as K8 (29, 45). In this
study we identified two RTA binding sites in the ORF 57 RRE
region. The first is the 31-bp 5⬘ region which also contains the
K8 consensus sequences (Fig. 1), and the second site overlaps
with the first site and is located towards the 19-bp 3⬘ region of
the RRE. The second site, but not the first site, can be used by
both RTA and IRF-7, and RTA appears to bind with a stronger affinity to the second site based on our mobility shift analysis (Fig. 5A and B).
The presence of two RTA binding sites in the ORF 57 RRE
suggests that two RTA molecules can bind to the RRE either
as a dimer or as two separate monomers. The two binding sites
are distinct; one is the RTA binding site, and the other is the
RTA/IRF-7 binding site. It is possible that the binding affinities
mediated by these two sites are quite different, and the binding
of one or both could even be mediated by a cellular factor, such
as RBPj (23). We also do not know whether the same binding
domain is used by RTA for each site. Thus, the affinity of RTA
for each binding site and the mechanism of binding need to be
further investigated. In addition, given the effective competition of RTA binding by IRF-7 to the second site and the close
proximity of the two sites, it is likely that RTA may bind as a
dimer to this ORF 57 RRE region. In our proposed model
(Fig. 7), we hypothesize that the binding of RTA to both sites
in the ORF 57 promoter RRE region will result in strong
activation of ORF 57 expression. In such a model, activation is
anticipated to be mediated via RTA dimerization and the
recruitment of other transcriptional factors and RNA polymerase to the promoter region. The displacement of at least one
RTA from the RRE upon binding of IRF-7 to the proposed
IRF-7 binding site would result in weak or no activation. It is
possible that HHV-8 uses the inhibitory effect of IRF-7 binding
to regulate between lytic and latent infection and that inhibition of ORF 57 expression by IRF-7 will favor latency. Further
study will be needed to provide evidence for or against this
hypothesis.
IFN inhibits HHV-8 lytic replication, possibly via suppression of RTA activity by IRF-7. IFN-␣ has been shown to have
strong inhibitory effects on HHV-8 gene expression. In addition, blocking of IFN-␣ with neutralizing antibodies resulted in
more-extensive cytopathic effects and more-efficient viral particle release in these cells (33). In vivo, IFN-␣ inhibits HHV-8
reactivation, reduces HHV-8 viral load in peripheral blood
mononuclear cells from patients with KS, and has been successfully used in therapy for KS (21, 33).
The mechanism whereby IFN represses HHV-8 replication
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FIG. 7. A proposed model for the repression of HHV-8 RTAmediated transactivation of ORF 57 by IRF-7. Strong activation represents the binding of RTA to two sites in the ORF 57 promoter RRE
region. Weak activation represents the displacement of at least one
RTA from the RRE upon binding of IRF-7 to the IRF-7 binding site.

is unclear. The effect could be mediated directly by IFN or
could be indirect via other IFN-induced cellular or viral genes.
In this study we showed that at least one IFN-induced cellular
protein, IRF-7, plays a role in inhibition. IRF-7 is one of the
most strongly induced cellular transcripts after de novo HHV-8
infection and TPA-stimulated reactivation (38). Using HHV8-infected and uninfected cells, we demonstrated that both
endogenously expressed and transfected IRF-7 can compete
for the RTA binding site within the ORF 57 RRE region and
inhibit RTA-mediated activation. This suggests that IFN-␣
might block HHV-8 reactivation and lytic replication through
the competition of IRF-7 with RTA by modulating downstream viral genes, such as ORF 57. Since the activation of the
ORF 57 promoter by RTA cannot be completely suppressed
even in the presence of excess of IRF-7 (Fig. 3A), it suggests
that other viral and/or cellular factors may also be involved in
regulating RTA transactivation during infection. Indeed, it has
recently been demonstrated that the HHV-8 latent nuclear
antigen protein also plays a role in regulating RTA function by
directly interacting with RTA (22). It is possible that other
IFN-induced genes, in addition to IRF-7, may also be involved
in modulating lytic HHV-8 replication. However, our demonstration that RNA interference specific for IRF-7 can eliminate the inhibitory effects of RTA-mediated ORF 57 gene
expression upon induction by IFN (Fig. 6B) argues against a
role for other cellular proteins or IRFs in mediating the inhibition of ORF 57 expression. At this point, it is premature to
assume that there is no role for other IRFs in modulation of
the expression of other HHV-8 genes. The roles of other IRFs,
as well as the role of four HHV-8-encoded IRF homologues, in
HHV-8 replication and/or latency are a topic of continuing
investigation.
IRF-7 is an important cellular factor involved in modulating
viral gene expression upon HHV-8 infection. It also plays a
major role in the interferon-mediated gene expression pathway
and the antiviral innate immune response. It is likely that
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IRF-7 could affect viral lytic replication via multiple mechanisms. One mechanism is the suppression of viral replication as
suggested by our study. In fact, it has recently been shown that
HHV-8 encodes a protein, ORF 45, which is expressed early
upon viral infection and blocks the phosphorylation and nuclear accumulation of IRF-7 (54). This countermeasure for
IRF-7 could be a mechanism that the virus has developed to
overcome the inhibitory effect of IRF-7 and therefore enable
the virus to go through lytic replication. Further analysis is
required to understand the interplay among IRF-7, RTA, and
ORF 45 in the regulation of HHV-8 RTA activity and lytic
replication.
Since RTA is sufficient for the induction of the viral lytic
cycle, the control of RTA-mediated expression is anticipated
to play a pivotal role in the maintenance of viral latency.
Certain protein modifications or negative regulatory factors
that inactivate RTA transactivation could serve to limit the
extent of lytic replication or may even lead to the abortion of
lytic replication (20). Our results support the recently published gene array data indicating that during early infection, in
the presence of interferon and IRF-7, ORF 50 was expressed,
followed by brief expression of a limited number of lytic viral
genes, but ORF 57 expression was not detected (20). This
could be due to the suppression of RTA-mediated ORF 57
activation by IRF-7, which then favors the establishment of
latency and persistent infection. Similarly, during reactivation,
the expression of RTA induced lytic replication, which then
induced interferon and IRF-7, and subsequently shut down
lytic replication to reestablish latency. Our results suggest that
IRF-7, one of the IFN-induced products, is usurped by the
virus to inhibit viral lytic reactivation, to maintain HHV-8
latency, and to escape from the host immune response. Our
study also suggests a complex interplay among RTA activation
pathways, the repression of those pathways by IRF-7, and the
potential regulation of this system by other viral proteins, such
as ORF 45. Such a system provides sensitivity to the cellular
environmental conditions that promote latency or lytic replication when appropriate and may provide mechanistic bases
for IFN-␣ therapy of Kaposi’s sarcoma and other HHV-8related diseases. This interplay between the host innate immunity and the ability of the invading virus to make use of the host
defense mechanism to regulate its own replication may be a
general mechanism not strictly limited to HHV-8.
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